Form 4: Teva Pharmaceuticals Director Acquires Shares

Teva Pharmaceuticals Director Tal Zvi Zaks acquired 7,242 restricted share units on May 28, 2026, as part of a compensation plan.

Summary

• Tal Zvi Zaks, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units (RSUs) on May 28, 2026.
• These RSUs represent a contingent right to receive one ordinary share or its cash equivalent upon settlement.
• The RSUs were granted on May 28, 2026, and are scheduled to vest on May 28, 2027.
• The acquisition was made under a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation and share acquisition by a director under a pre-arranged plan, rather than a significant new strategic development or financial performance indicator.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-planned and potentially non-insider trading related acquisition.

Future Outlook

The restricted share units are set to vest on May 28, 2027, at which point they will convert into ordinary shares or their cash equivalent.

Industry Context

StockSavvy.ai notes that director share acquisitions, particularly under Rule 10b5-1(c) plans, are common in the pharmaceutical industry as a method of executive compensation and alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, but it does not immediately impact share count or market value.
• Employees: This transaction is part of the executive compensation structure, reflecting standard practices for retaining key personnel.
• Management: The transaction aligns management's interests with those of shareholders through equity ownership.

Next Steps

• The restricted share units will vest on May 28, 2027.
• Upon vesting, the units will convert into ordinary shares or their cash equivalent.

Key Dates

Keywords

Teva Pharmaceuticals, Form 4, Insider Trading, Restricted Share Units, Director Compensation, Securities Exchange Act, Rule 10b5-1(c)